VYMADA FCT 49/51 Tablet 14's (N)

INTRODUCTION

VYMADA FCT 49/51 TABLET is a combination of Sacubitril and Valsartan which belongs to the group of medicines called Angiotensin receptor neprilysin inhibitors. VYMADA FCT 49/51 TABLET is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (New York Heart Association Class II-IV) and reduced ejection fraction.  

Heart failure occurs when the heart is weak and cannot pump enough blood to the lungs and to the rest of the body and it is characterized by symptoms such as breathlessness, fatigue, tiredness and ankle swelling. Before taking VYMADA FCT 49/51 TABLET inform your doctor if you have liver, kidney or heart problems.    

VYMADA FCT 49/51 TABLET is not recommended for use in pregnant and breast-feeding women. It is not suitable for use in children and adolescents under 18 years of age and it should be used with caution in elderly patients (65 years of age and above).    

Before taking VYMADA FCT 49/51 TABLET inform your doctor about previous allergy and medication history to prevent any serious effect.     

The most common side effects of taking VYMADA FCT 49/51 TABLET are dizziness, cough, headache, tiredness, nausea and weakness. Consult your doctor if any of the side effects worsen.

USES OF VYMADA FCT 49/51 TABLET

•  Treats long-term heart failure in adults

HOW VYMADA FCT 49/51 TABLET WORKS

VYMADA FCT 49/51 TABLET helps to treat long-term heart failure, where sacubitril works by relaxing and widening the blood vessels and makes it easier for the heart to pump blood throughout the body and valsartan works by relaxing the blood vessels by blocking a substance called angiotensin-II (causing blood vessels to tighten) which is produced in the body and thus lowers the blood pressure.

DIRECTIONS FOR USE

Take VYMADA FCT 49/51 TABLET as advised by your physician. Swallow VYMADA FCT 49/51 TABLET with a glass of water. Do not crush or chew the medicine. Your doctor will decide the correct dose and duration for you depending upon your age, body weight and disease condition.

SIDE EFFECTS OF VYMADA FCT 49/51 TABLET

HOW TO MANAGE SIDE EFFECTS

Diarrhea

Drink lot of fluids such as water or fruit juices to keep yourself hydrated. Avoid taking any medicine on your own for treating diarrhea. Consult your doctor if the symptom did not improve.

Headache

Rest and relax. Drink plenty of fluids such as water or electrolytes. Apply a pain-relieving balm on the forehead if required. Do not consume too much of alcohol. Consult your doctor if the symptom did not improve.

Nausea And Vomiting

Stick to simple meals. Avoid eating oily, fried and spicy foods. Do not perform any strenuous activities immediately after eating. Consult your doctor if the symptom did not improve.

Tiredness

Drink plenty of fluids and eat balanced diet and frequent meals. Do regular minimal exercise and follow regular sleep schedule. Consult your doctor if your symptom did not improve.

WARNING & PRECAUTIONS

PREGNANCY

Contraindicated

VYMADA FCT 49/51 TABLET is not recommended for use in early pregnancy and must not be used in pregnant women when more than 3 months pregnant, as it may cause serious harm to the baby. Consult your doctor before taking VYMADA FCT 49/51 TABLET if you think you may be pregnant.

BREASTFEEDING

Contraindicated

VYMADA FCT 49/51 TABLET is not recommended for use in breastfeeding women. Consult your doctor before taking VYMADA FCT 49/51 TABLET if you are breast-feeding or about to start breast-feeding.

DRIVING AND USING MACHINES

Use with Caution

Avoid driving or handling any machines while taking VYMADA FCT 49/51 TABLET because it may cause dizziness or tiredness.

KIDNEY

Use with Caution

VYMADA FCT 49/51 TABLET should be used with caution in patients with severe kidney disease and with narrowed kidney artery. Consult your doctor before taking VYMADA FCT 49/51 TABLET.

LIVER

Consult your doctor

VYMADA FCT 49/51 TABLET is not recommended for use in patients with severe liver disease and it should be used with caution in patients with liver disease. Consult your doctor before taking VYMADA FCT 49/51 TABLET.

ALLERGY

Consult your doctor

Do not take VYMADA FCT 49/51 TABLET if you are allergic (hypersensitive) to Sacubitril and Valsartan.

USE IN PEDIATRICS

Contraindicated

VYMADA FCT 49/51 TABLET is generally not recommended for use in children and adolescents (under 18 years of age). Consult your child’s doctor for advice.

USE IN GERIATRICS

Use with Caution

VYMADA FCT 49/51 TABLET should be used with caution in elderly patients (above 65 years of age). Consult your doctor before taking VYMADA FCT 49/51 TABLET.

INTERACTIONS

A. Drug-Drug interactions:

Before taking VYMADA FCT 49/51 TABLET inform to your doctor, if you are taking any of these medicines: 

• enalapril, lisinopril or ramipril (treats high blood pressure)
• aliskiren and angiotensin receptor blockers such as telmisartan, losartan (treats heart failure)
• atorvastatin (lowers high cholesterol levels)
• sildenafil (treats erectile dysfunction or lung hypertension)
• potassium supplements, salt substitutes containing potassium, potassium-sparing medicines such as spironolactone (used to increase potassium levels in blood)
• heparin, warfarin (treats blood clot)
• non-steroidal anti-inflammatory medicines (NSAIDs) such as ibuprofen, indomethacin or selective cyclooxygenase-2 (Cox-2) inhibitors such as celecoxib (treats pain and inflammation)
• lithium (used to treat psychiatric illness)
• furosemide (used to increase the amount of urine)
• nitroglycerine (treats angina pectoris)
• rifamycin (treats bacterial infections)
• ciclosporin (used to prevent rejection of transplanted organs)
• ritonavir (used to treat HIV/AIDS)
• metformin (treats diabetes)

Overdosage:

If you or anyone else accidentally take too much of VYMADA FCT 49/51 TABLET, contact your doctor immediately or go to a nearest hospital straight away. Overdosage symptoms of VYMADA FCT 49/51 TABLET includes severe dizziness and fainting.

SYNOPSIS

MORE INFORMATION

• Keep out of reach of children
• Do not store above 30°C

FAQs ABOUT VYMADA FCT 49/51 TABLET

Q: What is VYMADA FCT 49/51 TABLET used for?

A: VYMADA FCT 49/51 TABLET is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (New York Heart Association Class II-IV) and reduced ejection fraction.

Q: What are the common side effects of taking VYMADA FCT 49/51 TABLET?

A: The most common side effects of taking VYMADA FCT 49/51 TABLET are dizziness, light-headedness (low blood pressure), signs of high levels of potassium in the blood (irregular heartbeat, muscle weakness), decrease in renal function, cough, diarrhea, signs of low red blood cells (anemia), tiredness, headache, fainting or spinning sensation. Consult your doctor immediately if any of the side effects worsen.

Q: Can VYMADA FCT 49/51 TABLET be used in pregnant women?

A: No, VYMADA FCT 49/51 TABLET is not recommended for use in early pregnancy and must not be used in pregnant women when more than 3 months pregnant, as it may cause serious harm to the baby. Consult your doctor before taking VYMADA FCT 49/51 TABLET if you think you may be pregnant.

Q: Is VYMADA FCT 49/51 TABLET safe to use in liver disease patients?

A: VYMADA FCT 49/51 TABLET is not recommended for use in patients with severe liver disease and it should be used with caution in patients with liver disease. Consult your doctor before taking VYMADA FCT 49/51 TABLET.

Q: What to do If I forget to take VYMADA FCT 49/51 TABLET?

A: You should take VYMADA FCT 49/51 TABLET immediately when you remember. If it is time for your next dose skip the missed dose and follow your regular dose schedule. Do not double the dose to match up your missed dose.

REFERENCES

1. KD Tripathi MD. Cardiovascular drugs. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, May 2013. Page – 508.

2. Loretta Fala. Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure. NCBI; PMC. Pubmed Central. National Library of Medicine, National Institute of Health. September 2018. [Accessed on 1st July 2021] ncbi.nlm.nih.gov/pmc/articles/PMC4636283/

3. Peter Khalil, Ghazal Kabbach, Sarmad Said and Debabrata Mukherje. Entresto, a New Panacea for Heart Failure. NIH National Library of Medicine, National center for biotechnology information. Pubmed.gov. 2018. [Accessed on 1st July 2021] https://pubmed.ncbi.nlm.nih.gov/29532764/

4. Novartis Pharmaceuticals UK Ltd. Electronic Medicines Compendium (EMC) [Revised in May 2021] [Accessed on 1st July 2021] https://www.medicines.org.uk/emc/files/pil.7751.pdf

5. Cipla Ltd. Azmarda Tablets (Sacubitril/Valsartan). Ciplamed. [Revised in March 2017] [Accessed on 1st July 2021] https://www.ciplamed.com/content/azmarda-tablets

USEFUL DIAGNOSTIC TESTS

• Electrolyte panel

AUTHOR DETAILS

Written By Dr. R. Dinesh John Rajkumar, Pharm.D
Last updated on 20 Mar 2023 | 09:09 AM(IST)